Browsing by Author "Jallinoja, Vilma"

Prostate cancer is the most common cancer in male population in the western world. In Finland around 5000 men are diagnosed with it every year. Most patients are diagnosed with localized prostate cancer, when the prognosis is good: the relative 5-year survival is over 90%. The metastasized form of prostate cancer can be considered fatal, since the 5-year survival rate for patients with metastases in distant organs is about 29%. Early diagnosis and clear and definite understanding of patient's tumor profile are fundamental parts of optimized treatment of prostate cancer. Proliferation and antiapoptotic characteristics of prostate cancer tissue is caused by altered androgen receptor signaling. Many treatment forms of prostate cancer are concentrating on inhibiting this signaling pathway. Furthermore expression of androgen receptors is increased in prostate cancer tissue compared to healthy tissue. These factors corroborate that androgen receptor is a good candidate for targeting and imaging prostate cancer. With positron emission tomography tracers it is possible to quantitatively detect receptors in vivo. Selective androgen receptor modulators are class of drug molecules that alter androgen receptor activity. They have high affinity to androgen receptor. The aim of this master's thesis was to produce a fluorine-18 and/or iodine-131 labelled selective androgen receptor modulator derivative that could be used for imaging androgen receptor lesions in metastatic prostate cancer. Two different selective androgen receptor modulators were investigated. The second one, a 4-(pyrrolidin-1-yl) benzonitrile derivative was labelled successfully with iodine-131. Its binding to androgen receptor was tentatively shown with LnCapAR cell line. The radiolabelled compound showed binding to androgen receptor with IC50 value of 0.1903 nM.